Approval · Notice of Compliance 23826 · 2020
UPTRAVI: Notice of Compliance 23826
Issued June 23, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23826
- Date
- June 23, 2020
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add a new dosing recommendation with co-administration of UPTRAVI and moderate Cytochrome P450 (CYP) 2C8 inhibitors.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| UPTRAVI | Not yet assigned | — |